growth-hormone
Research Use OnlyCJC-1295 / Ipamorelin
A blend of CJC-1295, a synthetic GHRH analogue, and Ipamorelin, a selective ghrelin/GHS-R1a receptor agonist. Characterized in pre-clinical literature for their combined action on the somatotropic axis and pulsatile growth-hormone secretagogue pathways. Sold for laboratory research and identification purposes only. Not for human consumption.
Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
Subscribe & save: $146
Quantity
Add 1 more to save 10% per unit
Technical Data
Specifications
Technical Details
Bulk Pricing
Volume Pricing Guide
Quality Assurance
Certificate of Analysis
Certificate of Analysis
Research Overview
About CJC-1295 / Ipamorelin
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue that employs Drug Affinity Complex (DAC) technology to achieve covalent albumin binding in circulation, extending its biological half-life from minutes to approximately 6–8 days. This sustained presence enables continuous stimulation of pituitary somatotrophs and prolonged elevation of both growth hormone and IGF-1 levels in research models.
Ipamorelin is a pentapeptide growth hormone secretagogue receptor (GHS-R1a) agonist that triggers GH release through the ghrelin signaling pathway — mechanistically independent of GHRH. Its defining characteristic is selectivity: unlike earlier secretagogues such as GHRP-6, ipamorelin stimulates growth hormone release with minimal concomitant increases in cortisol, prolactin, or ACTH, producing a cleaner pharmacological profile.
The combination leverages convergent signaling on somatotroph cells — simultaneous GHRH receptor and ghrelin receptor activation produces synergistic GH pulse amplification exceeding either agent alone. ROEHN supplies this blend at 99% HPLC-verified purity (each component) as a co-lyophilized powder, supporting research into IGF-1 kinetics, body composition, sleep architecture, and recovery in aging and performance models.
